Hans Joachim Wallny

Company: Novartis Pharma AG
Hans Joachim

Dr. Hans-Joachim Wallny is a Technical project leader at the departement „Process Sciences and Production“, Novartis Pharma AG Switzerland. He was leading the technical team who recently achieved the approval of a monoclonal antibody (ILARIS) for the treatment of a rare autoinflammatory disease (CAPS) in US, EU and Switzerland.

Before this assignment he was head of a bioanalytics group, responsible for the development and validation of biological potency assays and high molecular impurity assays for bio¬pharmaceuticals during early development. Before he was head of the bioassay group, which included the responsibility for routine performance of bioassays for marketed products.

One of his main scientific ambitions was to develop and implement modern, fast and reliable bioassays using early cellular events as read-outs (e.g. reporter gene assays, KIRA assays, etc.). For this he was honored with the title “Novartis Leading Scientist” in 2003.

Prior to joining Novartis in 1997, he was a Lab head in the Biotechnology departement, Research and Development of Biotest Pharma GmbH, Germany, responsible for the development of bioanalytical methods and analytics for preclinical/clinical trials (1995-1997).

Dr. Wallny was previously a Scientist at the Basel Institute for Immunology, Switzerland (1992-1995) after receiving his Ph.D. degree in Biochemistry/Immunology from the University of Tübingen, Germany. Dr. Wallny received a diploma in biochemistry from the University of Tübingen, Germany in 1989.